Travere Therapeutics (TVTX) Q1 2026 earnings review
Major FSGS Approval Secured, But Q1 GtN Dynamics Stunt Sequential Revenue
Travere executed its most critical milestone of the year: securing FDA approval for FILSPARI in FSGS, effectively expanding its total addressable market to over 100,000 patients. The underlying demand remains exceptionally strong, with Patient Start Forms (PSFs) hitting a record 993 in Q1. However, the financials tell a distorted story due to seasonal dynamics. Despite a 9.4% sequential jump in PSFs, FILSPARI sales decelerated sharply, growing just 1.8% sequentially to $105.2M. This revenue/volume disconnect stems from expected Q1 Gross-to-Net (GtN) discounts. Meanwhile, heavy SG&A investments for the FSGS launch compressed Non-GAAP Net Income down to $4.1M.
🐂 Bull Case
The April FDA approval in FSGS expands the addressable market by >30,000 patients. First patients were treated within a week, validating Travere's pre-launch operational readiness and the high unmet medical need.
Achieving 993 PSFs is a massive beat that solidifies FILSPARI's position as foundational care in IgAN, shrugging off emerging competitor threats.
🐻 Bear Case
The gap between volume growth (+9.4% QoQ) and revenue growth (+1.8% QoQ) is glaring. High Q1 GtN discounts, exacerbated by Medicare Part D redesigns, are severely suppressing top-line realization.
Non-GAAP Net Income plunged from $33.3M in 25Q4 to $4.1M in 26Q1. While the FSGS commercial scale-up is necessary, it is burning through the profitability gains made in late 2025.
⚖️ Verdict: 🟢
Bullish. The sequential revenue stall is ugly on the surface but fundamentally driven by known Q1 payer dynamics. The core business—patient demand and regulatory execution—is flawless, setting the stage for aggressive revenue re-acceleration as FSGS numbers hit the P&L in Q2 and Q3.
Key Themes
Immediate FSGS Commercial Execution
The FDA approved FILSPARI for FSGS on April 13, 2026. Management wasted no time, generating start forms on day one and dosing patients within the first week. This segment has no other FDA-approved medicines, an estimated 30,000+ U.S. patient population, and leverages an 80% prescriber overlap with the existing IgAN sales force. It is the company's premier growth catalyst for 2026.
IgAN Demand Keeps Accelerating
FILSPARI received 993 new PSFs in Q1, accelerating from 908 in Q4 and 731 in Q3. This sustained acceleration proves that FILSPARI is establishing itself as the new standard of care (replacing RAS inhibitors), and is effectively neutralizing the threat of newly launched competitors in the IgAN space.
Pegtibatinase Phase 3 HARMONY Advances
Travere successfully dosed the first new patient in the restarted pivotal Phase 3 HARMONY study for classical HCU. With topline data anticipated in 2H 2027, the company is successfully advancing its next potential first-in-class, disease-modifying therapy beyond its core nephrology franchise.
Gross-to-Net Squeeze Suppresses Revenue
A key contradiction in the positive volume narrative: PSFs surged from 908 to 993 sequentially, yet FILSPARI revenue barely budged ($103.3M to $105.2M). Management warned in the Q4 call that Medicare Part D redesign and standard Q1 insurance resets would spike GtN discounts to the 'mid-20s' percentage. This data point proves the severity of that margin headwind.
SG&A Load Crushes Profitability
Travere's Non-GAAP Net Income compressed violently to $4.1M in Q1, a stark deceleration from $33.3M in Q4 2025. This was driven by GAAP SG&A expenses ballooning 33% YoY to $80.3M. While expanding the sales force past 100 reps for the FSGS launch is necessary, the operating leverage story has taken a temporary step backward.
Legacy Tiopronin Franchise Fading
Tiopronin product sales remained stable but structurally declining at $19.3M, compared to $20.0M in the prior year. Management previously guided for incoming generic competition to erode this segment. Investors should view this cash cow as a melting ice cube.
Other KPIs
Grew 56% YoY, driven entirely by FILSPARI's $105.2M product sales. License and collaboration revenue contributed $2.7M, down from $5.9M a year ago. Total product sales represented $124.5M.
Accelerated 22% YoY from $46.9M in 25Q1. Management specifically noted the increase is attributable to the restart activities for the pivotal Phase 3 HARMONY Study of pegtibatinase, marking a renewed commitment to long-term pipeline development.
Decreased from $322.8M at the end of 2025, largely due to operating burn and milestone timings. However, this balance excludes a $25M sales-based milestone from Mirum Pharmaceuticals that was received in April 2026, putting effective liquidity closer to $290M. Management previously stated no near-term need for capital raises.
Guidance
New milestone targeted. Following the dosing of the first new patient in the restarted HARMONY trial, the company has officially anchored the next major pipeline readout to the back half of 2027. This provides a clear timeline for assessing its disease-modifying potential in classical HCU.
Partner Chugai Pharmaceutical remains on track to submit the NDA in Japan this year. This serves as a key international regulatory catalyst that will trigger future milestone and royalty payments for Travere.
Key Questions
FSGS Off-Label Normalization
Of the record 993 PSFs generated in Q1, how many were anticipatory, off-label prescriptions for FSGS leading up to the April 13 approval? We need to understand if the core IgAN volume is inflated.
Gross-to-Net Recovery Path
With Q1 bearing the brunt of the Medicare Part D redesign and insurance resets, what is the exact timeline and magnitude for GtN recovery in Q2 and Q3? Will revenue growth re-couple with volume?
SG&A Run Rate
GAAP SG&A hit $80.3M this quarter to prep for FSGS. With the sales force expansion complete and the drug approved, is $80M the new quarterly baseline, or will these launch-prep costs moderate in the back half of the year?